NCT02525588

Brief Summary

Comparison of conventional UHMWPE (ultra-high-molecular-weight polyethylene) with highly cross-linked polyethylene (X3) in a condylar stabilizing (CS) fixed bearing total knee prosthesis by means of RSA and clinical evaluation.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Sep 2011

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2011

Completed
3.8 years until next milestone

First Submitted

Initial submission to the registry

June 11, 2015

Completed
2 months until next milestone

First Posted

Study publicly available on registry

August 17, 2015

Completed
3.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 28, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 28, 2019

Completed
1 year until next milestone

Results Posted

Study results publicly available

April 7, 2020

Completed
Last Updated

February 22, 2024

Status Verified

February 1, 2024

Enrollment Period

7.6 years

First QC Date

June 11, 2015

Results QC Date

March 12, 2020

Last Update Submit

February 20, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Assessment of Polyethylene Inlay Wear by Roentgen Stereophotogrammetric Analysis (RSA).

    RSA is a highly accurate technique for the assessment of three-dimensional migration and micro motion of a joint replacement prosthesis relative to the bone it is attached to. Because of the high accuracy, RSA can also be used to measure wear in knee replacements and is used in this study for the assessment of the wear of the two polyethylene inlay types N2Vac polyethylene and X3 polyethylene.

    1, 2 and 5 years follow-up

Secondary Outcomes (5)

  • Assessment of Prosthetic Migration Results After Two Years by RSA.

    3 and 6 months,1, 2 and 5 years follow-up

  • Investigation of Clinical Performance and Patient Outcome With the Knee Society Score (KSS)

    Pre-operative, 6 weeks, 3 and 6 months, 1, 2 and 5 years

  • Investigation of Clinical Performance and Patient Outcome With the Short Form Patient Questionnaire (SF-36)

    Pre-operative, 6 weeks, 3 and 6 months, 1, 2 and 5 years

  • Investigation of Clinical Performance and Patient Outcome With the EuroQuol - 5 Dimension (EQ-5D) Patient Questionnaire

    Pre-operative, 6 weeks, 3 and 6 months, 1, 2 and 5 years

  • Investigation of Clinical Performance and Patient Outcome With the Lower Extremity Activity Scale (LEAS) Patient Questionnaire

    Pre-operative, 6 weeks, 3 and 6 months, 1, 2 and 5 years

Study Arms (2)

Conventional polyethylene inlay nitrogen/vacuum-packed (N2Vac)

ACTIVE COMPARATOR

Conventional UHMWPE inlay in a Triathlon Condyle Stabilizing (CS) fixed bearing total knee prosthesis

Device: Triathlon CS fixed bearing total knee prosthesis

Highly cross-linked polyethylene (X3)

ACTIVE COMPARATOR

X3 highly cross-linked polyethylene inlay in a Triathlon CS fixed bearing total knee prosthesis

Device: Triathlon CS fixed bearing total knee prosthesis

Interventions

The patient will receive either the N2Vac polyethylene inlay or the X3 polyethylene inlay for their CS total knee.

Conventional polyethylene inlay nitrogen/vacuum-packed (N2Vac)Highly cross-linked polyethylene (X3)

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patient is able to understand the meaning of the study and is willing to sign the Ethic Commission approved, study specific Informed Patient Consent Form.
  • Patients with a pre-operative knee score of \< 70.
  • Patients scheduled to undergo primary total knee replacement with any of the following indication.
  • Painful and disabled knee joint resulting from osteoarthritis.
  • One or more compartments are involved.
  • Need to obtain pain relief and improve function.
  • Ability and willingness to follow instructions, including control of weight and activity level, and to return for follow-up evaluations.
  • A good nutritional state of the patient.
  • Full skeletal maturity of the patient, patients who are at least 18 years of age.
  • Patients of either sex.

You may not qualify if:

  • The subject is morbidly obese, defined as Body Mass Index (BMI) of \> 40.
  • Skeletal immaturity of the patient, patients who are less than 18 years of age.
  • Patient has a flexion contracture of 15° and more.
  • Patient has a varus/valgus contracture of 15° and more.
  • Patients with a pre-operative knee score of \>70.
  • The subject has a history of total or unicompartmental reconstruction of the affected joint.
  • The subject will be operated bilaterally.
  • Patients who had a Total Hip Arthroplasty (THA) on contralateral and/or ipsilateral side within the last year that is considered to have an unsatisfactory outcome (Patients with contralateral and/or ipsilateral THA \> 1 year ago with good outcome can be included in the study).
  • Patients who had a Total Knee Arthroplasty (TKA) on contralateral side within the last 6 months that is considered to have an unsatisfactory outcome. (Patients with contralateral TKA \> 6 months ago with good outcome can be included in the study).
  • The subject has an active or suspected latent infection in or about the knee joint.
  • Osteomyelitis.
  • Sepsis.
  • Patients who will need lower limb joint replacement for another joint within one year.
  • The subject has a neuromuscular or neurosensory deficiency, which would limit the ability to assess the performance of the device.
  • The subject has a systemic or metabolic disorder leading to progressive bone deterioration.
  • +5 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Orthopaedics 't Langeland Ziekenhuis Zoetermeer

Zoetermeer, South Holland, 2725 NA, Netherlands

Location

Results Point of Contact

Title
Britta von den Brincken, Clinical Study Manager
Organization
Stryker

Study Officials

  • H. Kaptijn, MD

    't Langeland Ziekenhuis Zoetermeer

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
LTE60
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 11, 2015

First Posted

August 17, 2015

Study Start

September 1, 2011

Primary Completion

March 28, 2019

Study Completion

March 28, 2019

Last Updated

February 22, 2024

Results First Posted

April 7, 2020

Record last verified: 2024-02

Locations